Production (Stage)
COSCIENS Biopharma Inc.
CSCI
$3.68
$0.113.08%
NASDAQ
| 03/31/2025 | 12/31/2024 | 06/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -- | -- | 102.73% | 102.73% | 105.04% |
| Total Depreciation and Amortization | -- | -- | 166.88% | 166.88% | 354.15% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -- | -- | -136.82% | -136.55% | -110.60% |
| Change in Net Operating Assets | -- | -- | 530.25% | 530.25% | 126.42% |
| Cash from Operations | -- | -- | 122.00% | 122.23% | 119.77% |
| Capital Expenditure | -- | -- | -2,895.83% | -2,895.83% | -3,608.33% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -700.00% | -700.00% | -700.00% |
| Cash from Investing | -- | -- | 50,285.71% | 50,285.71% | -3,529.73% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -144.00% | -155.00% | -176.83% |
| Issuance of Common Stock | -- | -- | 1,200.00% | 1,200.00% | 1,200.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -- | -159.56% | -171.58% | -200.00% |
| Foreign Exchange rate Adjustments | -- | -- | -231.11% | -228.89% | 129.17% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -- | -- | 383.09% | 383.09% | 107.09% |